GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
The induction of nausea and emesis is a major barrier to maximizing the weight loss profile of obesity medications, and therefore, identifying mechanisms that improve tolerability could result in added therapeutic benefit. The development of peptide YY (PYY)-based approaches to treat obesity are no...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 71; no. 7; pp. 1410 - 1423 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Diabetes Association
01.07.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 0012-1797 1939-327X 1939-327X |
DOI | 10.2337/db21-0848 |
Cover
Loading…